PDF(Pubmed)
Abstract：
UNASSIGNED: Research on the relationship between mild COVID-19 and the subsequent development of isolated optic neuritis (ON) with antibodies specific to myelin oligodendrocyte glycoprotein (MOG-ON) and aquaporin 4 (AQP4-ON) is limited, particularly case-control studies that directly compare these conditions within the same affected population.
UNASSIGNED: A retrospective analysis of initial MOG-ON and AQP4-ON cases during the COVID-19 peak and subsequent months. Patients were classified as possible COVID-19 related ON (PCRON) or non-COVID-19 related ON (NCRON). The study compared epidemiology, comorbidities, and clinical features between these groups.
UNASSIGNED: Patients with MOG-ON tended to develop ON symptoms closer in time to a mild COVID-19 infection compared to those with AQP4-ON (6.87 ± 6.25 weeks vs. 11.06 ± 5.84 weeks; p = 0.038), a significantly higher proportion of patients with MON-ON developing symptoms within 6 weeks after COVID-19 compared to those with AQP4-ON (15/23 [65.2%] vs. 5/17 [29.4%]; p = 0.025). Comparing MOG-ON and AQP4-ON patients, MOG-ON patients were more likely to have a recent infection before ON onset (73.1% vs. 30%; p = 0.007) and had better peak and post-treatment visual acuity (p = 0.01; p < 0.001). In contrast, AQP4-ON patients frequently showed comorbid connective tissue diseases (30.0% vs. 0%, p = 0.004) and antinuclear antibody abnormalities (40.0% vs. 7.7%, p = 0.012). Among MOG-ON patients, PCRON had increased rates of atherosclerotic vascular diseases (AVDs) (53.3% vs. 9.1%, p = 0.036), phospholipid antibody abnormalities (60.0% vs. 18.2%, p = 0.04), and bilateral visual impairment (66.7% vs. 9.1%, p = 0.005). Multivariate analysis pinpointed AVDs (OR = 15.21, p = 0.043) and bilateral involvement (OR = 25.15, p = 0.015) as independent factors related to COVID-19 associated MOG-ON, with both being good discriminators for PCRON (AUC = 0.879). No differences were found between the PCRON and NCRON groups in AQP4-ON patients.
UNASSIGNED: Mild COVID-19 is more likely associated with MOG-ON than AQP4-ON. MOG-ON that develops within 6 weeks following a COVID-19 infection may be associated with the COVID-19 infection. AVDs may have a synergistic effect on MOG-ON in patients with COVID-19, which warrants further investigation. COVID-19 related MOG-ON often affects both eyes, and acute visual function damage can be severe, but generally has a good prognosis.
UNASSIGNED: A retrospective analysis of initial MOG-ON and AQP4-ON cases during the COVID-19 peak and subsequent months. Patients were classified as possible COVID-19 related ON (PCRON) or non-COVID-19 related ON (NCRON). The study compared epidemiology, comorbidities, and clinical features between these groups.
UNASSIGNED: Patients with MOG-ON tended to develop ON symptoms closer in time to a mild COVID-19 infection compared to those with AQP4-ON (6.87 ± 6.25 weeks vs. 11.06 ± 5.84 weeks; p = 0.038), a significantly higher proportion of patients with MON-ON developing symptoms within 6 weeks after COVID-19 compared to those with AQP4-ON (15/23 [65.2%] vs. 5/17 [29.4%]; p = 0.025). Comparing MOG-ON and AQP4-ON patients, MOG-ON patients were more likely to have a recent infection before ON onset (73.1% vs. 30%; p = 0.007) and had better peak and post-treatment visual acuity (p = 0.01; p < 0.001). In contrast, AQP4-ON patients frequently showed comorbid connective tissue diseases (30.0% vs. 0%, p = 0.004) and antinuclear antibody abnormalities (40.0% vs. 7.7%, p = 0.012). Among MOG-ON patients, PCRON had increased rates of atherosclerotic vascular diseases (AVDs) (53.3% vs. 9.1%, p = 0.036), phospholipid antibody abnormalities (60.0% vs. 18.2%, p = 0.04), and bilateral visual impairment (66.7% vs. 9.1%, p = 0.005). Multivariate analysis pinpointed AVDs (OR = 15.21, p = 0.043) and bilateral involvement (OR = 25.15, p = 0.015) as independent factors related to COVID-19 associated MOG-ON, with both being good discriminators for PCRON (AUC = 0.879). No differences were found between the PCRON and NCRON groups in AQP4-ON patients.
UNASSIGNED: Mild COVID-19 is more likely associated with MOG-ON than AQP4-ON. MOG-ON that develops within 6 weeks following a COVID-19 infection may be associated with the COVID-19 infection. AVDs may have a synergistic effect on MOG-ON in patients with COVID-19, which warrants further investigation. COVID-19 related MOG-ON often affects both eyes, and acute visual function damage can be severe, but generally has a good prognosis.
摘要：
■关于轻度COVID-19与随后发展的孤立性视神经炎（ON）与髓鞘少突胶质细胞糖蛋白（MOG-ON）和水通道蛋白4（AQP4-ON）特异性抗体之间关系的研究有限，特别是在同一受影响人群中直接比较这些条件的病例对照研究。
■对COVID-19高峰和随后几个月的初始MOG-ON和AQP4-ON病例的回顾性分析。患者被分类为可能的COVID-19相关ON（PCRON）或非COVID-19相关ON（NCRON）。这项研究比较了流行病学，合并症,和这些群体之间的临床特征。
■与AQP4-ON患者相比，MOG-ON患者倾向于在时间上更接近于轻度COVID-19感染（6.87±6.25周vs.11.06±5.84周；p=0.038），与AQP4-ON患者相比，MON-ON患者在COVID-19后6周内出现症状的比例明显更高(15/23[65.2%]与5/17[29.4%]；p=0.025）。比较MOG-ON和AQP4-ON患者，MOG-ON患者在ON发作前更有可能最近感染(73.1%vs.30％；p=0.007），并且具有更好的峰值和治疗后视力（p=0.01；p<0.001）。相比之下,AQP4-ON患者常表现为结缔组织病合并症(30.0%vs.0%,p=0.004）和抗核抗体异常（40.0％vs.7.7%,p=0.012)。在MOG-ON患者中，PCRON的动脉粥样硬化性血管疾病（AVDs）发病率增加（53.3%vs.9.1%，p=0.036),磷脂抗体异常（60.0%vs.18.2%,p=0.04),和双侧视力障碍(66.7%vs.9.1%，p=0.005)。多因素分析确定AVDs（OR=15.21，p=0.043）和双侧受累（OR=25.15，p=0.015）是与COVID-19相关MOG-ON的独立因素，两者都是PCRON的良好鉴别器(AUC=0.879)。在AQP4-ON患者中，PCRON和NCRON组之间没有发现差异。
■轻度COVID-19比AQP4-ON更可能与MOG-ON相关。COVID-19感染后6周内发生的MOG-ON可能与COVID-19感染有关。AVDs可能对COVID-19患者的MOG-ON有协同作用，值得进一步研究。与COVID-19相关的MOG-ON经常影响双眼，急性视觉功能损伤可能很严重，但总体预后良好。
■对COVID-19高峰和随后几个月的初始MOG-ON和AQP4-ON病例的回顾性分析。患者被分类为可能的COVID-19相关ON（PCRON）或非COVID-19相关ON（NCRON）。这项研究比较了流行病学，合并症,和这些群体之间的临床特征。
■与AQP4-ON患者相比，MOG-ON患者倾向于在时间上更接近于轻度COVID-19感染（6.87±6.25周vs.11.06±5.84周；p=0.038），与AQP4-ON患者相比，MON-ON患者在COVID-19后6周内出现症状的比例明显更高(15/23[65.2%]与5/17[29.4%]；p=0.025）。比较MOG-ON和AQP4-ON患者，MOG-ON患者在ON发作前更有可能最近感染(73.1%vs.30％；p=0.007），并且具有更好的峰值和治疗后视力（p=0.01；p<0.001）。相比之下,AQP4-ON患者常表现为结缔组织病合并症(30.0%vs.0%,p=0.004）和抗核抗体异常（40.0％vs.7.7%,p=0.012)。在MOG-ON患者中，PCRON的动脉粥样硬化性血管疾病（AVDs）发病率增加（53.3%vs.9.1%，p=0.036),磷脂抗体异常（60.0%vs.18.2%,p=0.04),和双侧视力障碍(66.7%vs.9.1%，p=0.005)。多因素分析确定AVDs（OR=15.21，p=0.043）和双侧受累（OR=25.15，p=0.015）是与COVID-19相关MOG-ON的独立因素，两者都是PCRON的良好鉴别器(AUC=0.879)。在AQP4-ON患者中，PCRON和NCRON组之间没有发现差异。
■轻度COVID-19比AQP4-ON更可能与MOG-ON相关。COVID-19感染后6周内发生的MOG-ON可能与COVID-19感染有关。AVDs可能对COVID-19患者的MOG-ON有协同作用，值得进一步研究。与COVID-19相关的MOG-ON经常影响双眼，急性视觉功能损伤可能很严重，但总体预后良好。
